Home > Healthcare > Pharmaceuticals > Drug Delivery > Oral Transmucosal Drugs Market

Oral Transmucosal Drugs Market Share

Report ID: GMI8477
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Oral Transmucosal Drugs Market Share

The oral transmucosal drugs industry is fragmented in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced product based on different technologies is among a key market strategy.

Oral Transmucosal Drugs Market Companies

Some of the eminent market participants operating in the oral transmucosal drugs industry include:

Aquestive Therapeutics, Inc
C.L.Pharm Co., Ltd.
Cure Pharmaceutical.
IntelGenx Technologies Corp
Jazz Pharmaceuticals, plc.
NAL Pharma
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Limited.
ZIM Laboratories Limited.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market Size for oral transmucosal drugs was worth around USD 34.3 billion in 2023 and is set to record around 6.7% CAGR from 2024-2032 driven by the increasing prevalence of chronic diseases coupled with the rising demand for oral transmucosal drugs.

Oral transmucosal drugs industry share from the tablets segment is anticipated to generate USD 30.1 billion by 2032 owing to the convenience and ease of administration offered by tablets contributing significantly to improved patient compliance.

North America market accounted for USD 13.5 billion in 2023 and is poised to grow at a notable rate from 2024-2032 owing to the increasing prevalence of diabetes in North America.

Some of the leading companies engaged in the industry are Aquestive Therapeutics, Inc, C.L.Pharm Co., Ltd., Cure Pharmaceutical., IntelGenx Technologies Corp, Jazz Pharmaceuticals, plc., NAL Pharma, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Limited., and ZIM Laboratories Limited.